Document is current
Any future updates will be listed below
-
Authors
Stejskal, Pavel
Goodarzi, Hani
Srovnal, Josef
Hajdúch, Marián
van ’t Veer, Laura J.
Magbanua, Mark Jesus M.
-
Funding
Funding for this research was provided by:
Ministry of Health of the Czech Republic (NV18-03-00470)
Ministry of Health of the Czech Republic (NV18-03-00470)
Ministry of Health of the Czech Republic (NV18-03-00470)
Ministry of Education, Youth and Sport of the Czech Republic (LM2018132)
Ministry of Education, Youth and Sport of the Czech Republic (LM2018132)
Ministry of Education, Youth and Sport of the Czech Republic (LM2018132)
European Union - Next Generation EU (LX22NPO5102)
European Union - Next Generation EU (LX22NPO5102)
European Union - Next Generation EU (LX22NPO5102)
European Regional Development Fund (ACGT CZ.02.1.01/0.0/0.0/16_026/0008448)
European Regional Development Fund (ACGT CZ.02.1.01/0.0/0.0/16_026/0008448)
European Regional Development Fund (ACGT CZ.02.1.01/0.0/0.0/16_026/0008448)
Era of Hope Scholar (W81XWH-2210121)
The National Institutes of Health (R01CA240984)
The National Institutes of Health (R01 CA255442)
The National Institutes of Health (R01 CA255442)
Breast Cancer Research Foundation (BCRF-20-142)
Cancer Cell Mapping Initiative (U54 CA274502)
UCSF Breast Oncology Program Research Development Award, and the Cancer Cell Mapping Initiative (7030559)
- License Information
-
More Information
Article History
Received: 3 November 2022
Accepted: 29 December 2022
First Online: 21 January 2023
Declarations
:
: Not applicable.
: HG is a stock-holder, board member, and Scientific advisor to ExaiBio Inc. LvtV reports ownership of stocks and part-time employment of Agendia Inc. and is an advisor to ExaiBio Inc. The remaining authors declare no competing interests.
